Moderate Dietary Supplementation with Omega-3 Fatty Acids Does Not Impact Plasma Von Willebrand Factor Profile in Mildly Hypertensive Subjects
Table 1
Subject demographics and clinical data for the different treatment groups.
Measurements
Treatment groups
Hypertensive n-3 PUFAs
Hypertensive placebo
Normotensive n-3 PUFAs
Normotensive placebo
Gender (F/M)
1/5
3/6
6/7
9/5
Age (years; mean ± SD)
45.7 ± 11.27
57.8 ± 10.29
51.1 ± 8.84
48.8 ± 8.84
BMI (kg/m2; mean ± SD)
33.5 ± 3.64*
28.6 ± 5.01
25.9 ± 4.04
27.0 ± 3.97
Medications
None
= 6
= 4
= 10
= 9
NSAIDs
= 1∧
= 1
Antidepressant
= 3
= 1
= 2
HRT
= 1∧
= 1
Contraceptive pill
= 1
Antiallergy
= 1
= 1
Paracetamol
= 1#
Thyroxine
= 1
Glucosamine
= 1#
Pygeum
= 1#
Methotrexate
= 1#
Smoking status
Current
= 2
= 2
= 2
= 1
Never
= 3
= 4
= 8
= 5
Previous
= 1
= 3
= 3
= 8
Blood pressure (mmHg)
SBP, baseline
142.92 ± 3.14**
142.69 ± 2.35**
115.20 ± 2.07
116.60 ± 2.50
SBP, week 12
138.43 ± 3.63**
139.94 ± 3.58**
112.38 ± 2.59
115.27 ± 2.76
DBP, baseline
91.44 ± 3.74**
85.75 ± 3.47**
74.07 ± 1.29
73.88 ± 1.59
DBP, week 12
90.68 ± 3.28**
85.68 ± 3.03**
73.01 ± 1.72
73.21 ± 2.15
Serum lipids (mM)
TC, baseline
4.35 ± 0.32
4.78 ± 0.43
4.93 ± 0.31
4.96 ± 0.33
TC, week 12
4.49 ± 0.34
4.69 ± 0.45
5.21 ± 0.33
5.04 ± 0.29
TG, baseline
1.33 ± 0.18
1.26 ± 0.34
1.06 ± 0.17
0.88 ± 0.10
TG, week 12
1.05 ± 0.13
0.95 ± 0.24
0.90 ± 0.14
0.99 ± 0.11
HDL-C, baseline
1.11 ± 0.13
1.48 ± 0.26
1.54 ± 0.17
1.67 ± 0.14
HDL-C, week 12
1.26 ± 0.12
1.66 ± 0.28
1.55 ± 0.18
1.70 ± 0.15
LDL-C, baseline
0.87 ± 0.20
0.93 ± 0.17
1.06 ± 0.13
1.10 ± 0.15
LDL-C, week 12
0.99 ± 0.15
0.95 ± 0.12
1.25 ± 0.13
1.07 ± 0.12
n-3 PUFAs: omega-3 polyunsaturated fatty acids; BMI: body mass index; NSAIDs: nonsteroidal anti-inflammatory drugs; HRT: hormone replacement therapy; multiple medications taken by the same subject; BP: blood pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure; SL: serum lipids; TC: serum total cholesterol; TG: serum triglycerides; HDL-C: serum high density lipoprotein cholesterol; LDL-C: serum low density lipoprotein cholesterol; * < 0.05 (hypertensive n-3 PUFA versus normotensive n-3 PUFA treatment group; one-way ANOVA); ** < 0.001 (hypertensive versus normotensive at baseline and week 12; one-way ANOVA). Data are expressed as mean ± SEM unless indicated otherwise.
